Floatz logo

cd33-car-t cell infusion

CAR T Cell Therapy

Qi dengCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the CAR T Cell Therapy cohort.

Asset / SponsorPhaseRating
Mb-Cart2019.1
Miltenyi Biomedicine GmbH
Phase 2B
HUMAN PERIPHERAL BLOOD LEUKOCYTES
The First Affiliated Hospital of Soochow University
Phase 2B
Anti-Cd19/Cd22 Car-T Cells
The First Affiliated Hospital of Soochow University
Phase 2B
cd19/baff-r in vivo car-t cell intravenous infusion
Qi deng
Phase 1CC

Same molecule, other indications

cd33-car-t cell infusion is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →